Title:
ANTI-GPRC5D ANTIGEN BINDING PROTEIN AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/030272
Kind Code:
A1
Abstract:
An isolated antigen binding protein, the antigen binding protein binding the protein G protein-coupled receptor, class C, group 5, member D (GPRC5D) at an EC50 value of 1.0 μg/mL. A chimeric antigen receptor comprising the antigen binding protein, and a use thereof in the treatment of tumors.
Inventors:
HE XIAOWEN (CN)
ZHOU JINCAI (CN)
CHEN SIYE (CN)
YANG YUE (CN)
SHI ZHONGJUN (CN)
LI XIAOPEI (CN)
ZHOU JINCAI (CN)
CHEN SIYE (CN)
YANG YUE (CN)
SHI ZHONGJUN (CN)
LI XIAOPEI (CN)
Application Number:
PCT/CN2022/115590
Publication Date:
March 09, 2023
Filing Date:
August 29, 2022
Export Citation:
Assignee:
ORICELL THERAPEUTICS CO LTD (CN)
International Classes:
C07K16/28; A61P35/00; A61P39/00; C07K16/30
Domestic Patent References:
| WO2020092854A2 | 2020-05-07 |
Foreign References:
| CN110462038A | 2019-11-15 | |||
| CN111788231A | 2020-10-16 | |||
| CN107428829A | 2017-12-01 |
Other References:
COHEN YOSSI; GUTWEIN ODIT; GARACH-JEHOSHUA OSNAT; BAR-HAIM ADINA; KORNBERG ABRAHAM: "GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells.", HEMATOLOGY, vol. 18, no. 6, 1 November 2013 (2013-11-01), pages 348 - 351, XP009195526, DOI: 10.1179/1607845413Y.0000000079
TATSUSHI KODAMA, KOCHI YU, NAKAI WAKA, MIZUNO HIDEAKI, BABA TAKESHI, HABU KIYOSHI, SAWADA NORIAKI, TSUNODA HIROYUKI, SHIMA TAKAHIR: "Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 9, 1 September 2019 (2019-09-01), US , pages 1555 - 1564, XP055743011, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-18-1216
FERNáNDEZ DE LARREA CARLOS, STAEHR METTE, LOPEZ ANDREA V., NG KHONG Y., CHEN YUNXIN, GODFREY WILLIAM D., PURDON TERENCE J., P: "Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma", BLOOD CANCER DISCOVERY, vol. 1, no. 2, 1 September 2020 (2020-09-01), pages 146 - 154, XP055847845, ISSN: 2643-3230, DOI: 10.1158/2643-3230.BCD-20-0020
TATSUSHI KODAMA, KOCHI YU, NAKAI WAKA, MIZUNO HIDEAKI, BABA TAKESHI, HABU KIYOSHI, SAWADA NORIAKI, TSUNODA HIROYUKI, SHIMA TAKAHIR: "Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 9, 1 September 2019 (2019-09-01), US , pages 1555 - 1564, XP055743011, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-18-1216
FERNáNDEZ DE LARREA CARLOS, STAEHR METTE, LOPEZ ANDREA V., NG KHONG Y., CHEN YUNXIN, GODFREY WILLIAM D., PURDON TERENCE J., P: "Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma", BLOOD CANCER DISCOVERY, vol. 1, no. 2, 1 September 2020 (2020-09-01), pages 146 - 154, XP055847845, ISSN: 2643-3230, DOI: 10.1158/2643-3230.BCD-20-0020
Attorney, Agent or Firm:
SHANGHAI DIANSHI PARTNERS, P.C. (CN)
Download PDF: